# EDGAR Filing Document

**Accession Number:** 0002099270
**File Stem:** 0001213900-26-064363
**Filing Date:** 2026-6
**Character Count:** 9784
**Document Hash:** 6eaf6dcba562ae2f91b93c61aa3d7745
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-064363.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001213900-26-064363

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bluejay Diagnostics, Inc.
- **CENTRAL INDEX KEY:** 0001704287
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 473552922
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93056
- **FILM NUMBER:** 261058650

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MASSACHUSETTS AVENUE, SUITE 203
- **CITY:** ACTON
- **STATE:** MA
- **ZIP:** 01720
- **BUSINESS PHONE:** (978) 631-0152

**MAIL ADDRESS:**
- **STREET 1:** 360 MASSACHUSETTS AVENUE, SUITE 203
- **CITY:** ACTON
- **STATE:** MA
- **ZIP:** 01720
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NORTHSTRIVE FUND II LP
- **CENTRAL INDEX KEY:** 0002099270

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 120 NEWPORT CENTER DR
- **STREET 2:** STE 250
- **CITY:** NEWPORT BEACH
- **STATE:** CA
- **ZIP:** 926660
- **BUSINESS PHONE:** 9498757003

**MAIL ADDRESS:**
- **STREET 1:** 120 NEWPORT CENTER DR
- **STREET 2:** STE 250
- **CITY:** NEWPORT BEACH
- **STATE:** CA
- **ZIP:** 926660

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Bluejay Diagnostics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Ross. D. Carmel, Esq.**<br>1185 Avenue of the Americas, 26th Floor<br>New York NY 10036<br>(212) 930-9700

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/02/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**NorthStrive Fund II LP** | Name of reporting person<br>**NorthStrive Fund II LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.00%** | Percent of class represented by amount in Row (11)<br>**0.00%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP ("Northstrive Fund"). On June 2, 2026, Northstrive Fund sold all of its previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Braeden Lichti** | Name of reporting person<br>**Braeden Lichti** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.00%** | Percent of class represented by amount in Row (11)<br>**0.00%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** On June 2, 2026, Mr. Lichti sold all of his previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Bluejay Diagnostics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
360 Massachusetts Avenue, Suite 203, Acton, MA, 01720

Mr. Braeden Lichti and Northstrive Fund previously filed a Schedule 13D on March 11, 2026. This Amendment No. 1 relates to the Common Stock of the Issuer and amends the Schedule 13G. The principal executive offices of the Issuer are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

Explanatory Note: This Amendment No. 1 ("Amendment No. 1") amends the Schedule 13D ("Schedule 13D") filed with the U.S. Securities and Exchange Commission ("SEC") on March 11, 2026 relates to the common stock of Bluejay Diagnostics, Inc. ("Issuer"), owned by the reporting persons hereto ("Reporting Persons") and is the final amendment to the Schedule 13D and an exit filing for the Reporting Persons.

**Item 4. Purpose of Transaction**

Since the filing of the Reporting Persons' Schedule 13D with the SEC on March 11, 2026, the Reporting Persons have disposed of all shares of common stock of the Issuer. As of June 2, 2026, the Reporting Persons no longer beneficially own any shares of the Issuer's Common Stock.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date of this Amendment, the Reporting Person do not beneficially own any shares of the Issuer's common stock. The information set forth on the cover pages of this Amendment is incorporated herein by reference.

**(b)**
Sole power to vote or to direct the vote:
Braeden Lichti: 0 shares
Northstrive Fund II LP: 0 shares

Shared power to vote or to direct the vote:
Braeden Lichti: 0 shares
Northstrive Fund II LP: 0 shares

Sole power to dispose or to direct the disposition of:
Braeden Lichti: 0 shares
Northstrive Fund II LP: 0 shares

Shared power to dispose or to direct the disposition:
Braeden Lichti: 0 shares
Northstrive Fund II LP: 0 shares

**(c)**
The information set forth in Item 3 above is incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information in Items 3 and 4 is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** NorthStrive Fund II LP

**Signature:** /s/ Braeden Lichti

**Name/Title:** Braeden Lichti/Manager

**Date:** 06/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Braeden Lichti

**Signature:** /s/ Braeden Lichti

**Name/Title:** Braeden Lichti/Manager

**Date:** 06/02/2026